VERONA PHARMA PLC

Analyst Reco. Verona Pharma plc London S.E.

Equities

VRP

GB00BYW2KH80

Delayed London S.E. Other stock markets 16:35:15 29/10/2020 GMT			5-day change	1st Jan Change
55 ^GBX	+5.77%		+4.76%	-11.29%

05-06	European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	MT
05-03	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, Set to Close Week Lower	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Raises Verona Pharma's Price Target to $36 From $31, Keeps Overweight Rating	04-16	MT
Wedbush Raises Verona Pharma Price Target to $33 From $30, Maintains Outperform Rating	13/09/23	MT
Truist Securities Adjusts Price Target on Verona Pharma to $32 From $28, Maintains Buy Rating	07/06/23	MT
Possibility of US Fed's Rate Hike Pause Supports American Depositary Receipts of European Equities	23/03/23	MT
BTIG Adjusts Price Target on Verona Pharma to $31 From $26, Maintains Buy Rating	20/03/23	MT
European Equities Move Lower Following ECB Rate Hike	02/02/23	MT
HC Wainwright Adjusts Verona Pharma's Price Target to $32 From $30, Keeps Buy Rating	21/12/22	MT
Wedbush Raises Verona Pharma's Price Target to $30 From $23, Maintains Outperform Rating	20/12/22	MT
Truist Securities Adjusts Price Target on Verona Pharma to $28 From $20, Maintains Buy Rating	20/12/22	MT
BTIG Boosts Price Target on Verona Pharma to $26 From $17, Reiterates Buy Rating	20/12/22	MT
ECB, Bank of England Interest Rate Hikes Weigh Down European Equities	15/12/22	MT
Wedbush Lowers Verona Pharma's Price Target to $23 From $27 Due to Increased Share Count, Keeps Outperform Rating	10/11/22	MT
Wedbush Analyst Assumes Coverage on Verona Pharma at Outperform With $27 Price Target, Up From $23	19/09/22	MT
HC Wainwright Adjusts Verona Pharma's Price Target to $30 From $25, Reiterates Buy Rating	29/08/22	MT
Piper Sandler Initiates Coverage on Verona Pharma With Overweight Rating, $31 Price Target	26/08/22	MT
Wedbush Raises Verona Pharma's Price Target to $23 From $18, Maintains Outperform Rating	09/08/22	MT
Wedbush Cuts Verona Pharma's Price Target to $18 From $25, Adjusting Ensifentrine Launch Estimates; Outperform Rating Kept	17/06/22	MT
Canaccord Genuity Adjusts Price Target on Verona Pharma to $23 From $18, Keeps Buy Rating	12/11/21	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019

Replicate our performance

fermer